Sanofi: Europe approves multiple myloma drug

(CercleFinance.com) - Sanofi has announced that the European Commission has approved Sarclisa (isatuximab), in combination with pomalidomide and dexamethasone (pom-dex), for the treatment of adults with relapsed or refractory multiple myeloma (MM).


This approval is for patients who have received at least two previous treatments - particularly lenalidomide and a proteasome inhibitor, and whose disease has progressed during the last treatment.

It is based on the positive results of a randomised phase III clinical trial (ICARIA-MM), where Sarclisa, combined with the pom-dex combination reduced the risk of disease progression or death by 40% compared to the pom-dex combination alone.


Copyright (c) 2020 CercleFinance.com. All rights reserved.